Amgen has agreed to buy rare disease drugmaker Horizon Therapeutics for $27.8 billion in cash, making the acquisition the largest pharma merger of the year.
Amgen on Monday said that it's agreed to buy rare disease drugmaker Horizon Therapeutics for $27.8 billion in cash.This is the year's largest pharma merger. It's also the richest acquisition ever for Amgen, which gets access to blockbuster thyroid eye disease drug Tepezza.That's nearly a 20% premium to Horizon's closing price last Friday, and a 47.
9% premium to Horizon's price before announcing on Nov. 29 it had received takeover approaches from Amgen, J&J and Sanofi.: "Tepezza's story is characteristic of those of treatments for ultra-rare diseases. Because of both advancements in science and the willingness of insurers and governments to pay for the new drugs, they have become among the most profitable bets in the drug business.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsAmgen is in advanced talks to buy drugmaker Horizon Therapeutics, people familiar with the matter say, in a deal likely to be valued at well over $20 billion
Read more »
Amgen reportedly in talks to buy Horizon TherapeuticsThe U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
Read more »
Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billionAmgen Inc. undefined said Monday it has agreed to acquire Horizon Therapeutics Plc undefined in an all-cash deal valued at $27.8 billion, confirming earlier...
Read more »
Amgen Agrees to Deal to Buy Horizon TherapeuticsThe U.S. biotech company agreed to buy drugmaker Horizon Therapeutics in a deal valued at $27.8 billion, marking the largest healthcare merger of the year.
Read more »
Amgen to buy Horizon Therapeutics in $26.4B dealAmgen is spending more than $26 billion to dive deeper into rare disease treatments with the acquisition of drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye disease that generated more than $1 billion in its first full year on the market.
Read more »
Amgen to buy Horizon Therapeutics in $26.4 billion dealAmgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare autoimmune diseases, in a deal valued at $26.4 billion.
Read more »